CEL-SCI awarded patent for LEAPS vaccine in treatment of RA
CEL-SCI Corporation announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, "Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis" for the company's LEAPS platform technology. CEL-SCI's LEAPS technology relates to peptide constructs which may be useful in the treatment or prevention of autoimmune diseases, particularly rheumatoid arthritis, asthma, allergies, and host versus graft rejection. The LEAPS platform technology is currently being developed as a potential therapeutic vaccine for rheumatoid arthritis under a $1.5M grant from National Institute of Arthritis and Musculoskeletal and Skin Diseases of the U.S. National Insitututes of Health. Upon completion of preclinical investigational new drug enabling studies for the LEAPS-based rheumatoid arthritis vaccine candidate, CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration to allow the rheumatoid arthritis vaccine to be tested in humans to determine its safety and potential therapeutic usefulness.